UK Food Standards Advisory Committee Sets Second Safety Review for Complex CBD Application RP450

The UK Advisory Committee on Novel Foods and Processes (ACNFP) released the formal agenda for its 178th meeting on September 9, 2026, scheduling a second scientific evaluation of full novel food application RP450 for September 16-17. Application RP450 represents a complex broad-spectrum cannabidiol formulation containing substantive levels of secondary cannabinoids, marking a critical step in establishing safety thresholds for multi-cannabinoid products in Great Britain.

This upcoming assessment comes alongside new updates from the Food Standards Agency (FSA) Board’s September 2026 meeting, where policy officers are summarizing public consultation responses ahead of long-term risk-management decisions for the commercial CBD sector in England, Wales, and Northern Ireland.

ACNFP Scientific Evaluation and Multi-Cannabinoid Safety

The 178th meeting of the ACNFP, taking place in London and online, focuses on completing hazard identification and evaluating technical data for RP450. Unlike simple CBD isolate products, broad-spectrum extracts contain additional naturally occurring cannabinoids such as CBG, CBC, and CBN alongside trace terpene profiles.

Key scientific issues under review by the committee include:

Toxicological Profile: Evaluating toxicological data and safety studies submitted by the applicant to establish acceptable daily intake levels for multi-cannabinoid extracts.
Reproductive Toxicity: Reviewing new evidence regarding reproductive and developmental safety in line with joint guidance developed by the ACNFP and Committee on Toxicity (COT) subgroup.
Quality Control and Stability: Assessing manufacturing consistency, batch-to-batch standardized cannabinoid profiles, and shelf-life stability data.
Exposure Assessment: Estimating potential daily consumer exposure when CBD products are consumed across food, tincture, and capsule formats.

FSA Policy Progress and Regulatory Landscape

Parallel to the ACNFP scientific review, the FSA Board’s September 2026 meeting confirmed that policy teams are finalizing a comprehensive summary of CBD consultation responses. This paper will guide future decisions regarding commercial novel food authorizations, product labeling rules, and compliance enforcement across Great Britain.

The FSA maintains its provisional guidance for healthy adult consumers, recommending a maximum daily intake of 10mg of CBD. The regulator advises that vulnerable groups, including pregnant or breastfeeding women, individuals taking prescription medication, and minors, avoid CBD products unless directed by a medical professional.

For consumers and retailers, products listed on the FSA’s public provisional list remain legal to sell while undergoing scientific evaluation. To learn more about buying compliant hemp products, read our guide on how to read a CBD Certificate of Analysis (COA), check our analysis of whether CBD is legal in Europe, or read about the latest French CBD trade challenge before the Conseil d’État.

Independent Testing and Verified European CBD Brands

While regulatory bodies review novel food dossiers, consumers should verify that any CBD oil or food supplement is backed by an independent batch Certificate of Analysis (COA) from an ISO/IEC 17025 accredited laboratory. Reliable brands clearly display total cannabinoid content, heavy metal screening, and verified THC levels below legal limits.

Verified European suppliers meeting stringent safety standards include:

Reakiro: Premium broad-spectrum CBD oils and capsules manufactured under certified European quality systems. Discover Reakiro CBD products.
SWISS FX: High-purity broad-spectrum CBD formulations tested for consistency and safety. Explore SWISS FX CBD options.
Cibdol: Swiss-formulated broad-spectrum CBD drops and topicals with complete batch lab reports. Compare Cibdol CBD oils.
Nordic Oil: Organic European hemp extracts tested for purity and cannabinoid profiles. View Nordic Oil CBD products.

Disclosure: cbd.eu.com provides independent editorial guidance. When you purchase through links on our site, we may earn an affiliate commission at no extra cost to you.

Frequently Asked Questions

What is application RP450 under review by the ACNFP?

Application RP450 is a full novel food application submitted to the UK Food Standards Agency for a broad-spectrum CBD product containing substantive levels of minor cannabinoids. The ACNFP is conducting its second scientific safety review during its 178th meeting on September 16-17, 2026.

Are CBD products still legal to purchase in the UK during the safety review?

Yes. CBD products that were on the market prior to February 2020 and have been submitted to the FSA novel food authorization process remain permitted for sale on the FSA provisional list while scientific evaluations proceed.

What is the current FSA daily intake recommendation for CBD?

The UK Food Standards Agency recommends that healthy adults consume no more than 10mg of CBD per day as a precautionary safety limit.